Janet Pope

Richard Conway, a vasculitis specialist, discusses pivotal findings from ACR 2024. Peter Nash delves into the role of JAK inhibitors, while Janet Pope reviews treatment strategies for polymyalgia rheumatica and giant cell arteritis. Eric Dian analyzes intriguing oral abstracts on rheumatoid arthritis, and David Liu emphasizes cardiovascular risks associated with treatments. They explore the safety of JAKs, advances in managing RA during COVID-19, and the efficacy of new therapies for PMR and GCA, showcasing innovative strategies for improving patient outcomes.

Join Professor Janet Pope and Dr Sofia Ramiro on The IMID Forum as they discuss the long-term safety of JAK inhibitors in RA. They delve into papers comparing tofacitinib versus TNFi in cardiovascular risk and the efficacy of upadacitinib over five years. The podcast also explores the importance of proper treatment to reduce risks and the balancing act of benefits versus risks in JAK inhibitor prescriptions for inflammatory diseases.